Tier 2 — strong

Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations

M Chopra, P E Fitzsimons, J J Strain, D I Thurnham, A N Howard
Clinical chemistry 2000 46(8 Pt 1):1162

Bibliography

PubMed
PMID 10926898
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized parallel supplementation comparison after a placebo run-in
ModelHuman intervention research
Sample21 men; 10 received quercetin and 11 red-wine extract
InterventionQuercetin 30 mg/day or nonalcoholic red-wine extract 1 g/day
Duration2-week placebo run-in, 2-week supplementation, 5-week washout
EndpointsLipid measurements; Oxidative-stress measures

What the study showed, in plain terms

Published in 2000, this source examined cardiovascular and metabolic health. Design: Randomized parallel supplementation comparison after a placebo run-in. Sample/model: 21 men; 10 received quercetin and 11 red-wine extract. The exposure or intervention was Quercetin 30 mg/day or nonalcoholic red-wine extract 1 g/day. Follow-up or treatment period: 2-week placebo run-in, 2-week supplementation, 5-week washout.

Ex vivo LDL resistance to copper-induced oxidation increased; plasma lipid levels did not change.

Small study of a laboratory oxidation assay, with placebo given sequentially. It does not establish reduced atherosclerosis or cardiovascular events.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Ex vivo LDL resistance to copper-induced oxidation increased; plasma lipid levels did not change.
  • The recorded outcome domains were Lipid measurements; Oxidative-stress measures.
  • The result applies to the tested exposure: Quercetin 30 mg/day or nonalcoholic red-wine extract 1 g/day; 2-week placebo run-in, 2-week supplementation, 5-week washout.

What this study can and cannot tell us

  • Small study of a laboratory oxidation assay, with placebo given sequentially. It does not establish reduced atherosclerosis or cardiovascular events.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 2
Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension
Valentyna Volodymyrivna Chopyak et al. · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2025
Tier 2
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN
Maryana I Prokosa et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2022
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology